Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$4.91 USD
+0.04 (0.82%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.90 -0.01 (-0.20%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum C VGM
Income Statements
Fiscal Year end for Aurinia Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 176 | 134 | 46 | 50 | 0 |
Cost Of Goods | 14 | 6 | 1 | 0 | 0 |
Gross Profit | 161 | 128 | 45 | 50 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 245 | 241 | 225 | 148 | 77 |
Income After Depreciation & Amortization | -83 | -113 | -180 | -97 | -76 |
Non-Operating Income | 9 | 7 | 0 | -5 | -47 |
Interest Expense | 3 | 0 | 0 | 0 | 0 |
Pretax Income | -77 | -106 | -180 | -103 | -124 |
Income Taxes | 1 | 2 | 1 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -78 | -108 | -181 | -103 | -124 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -78 | -108 | -181 | -103 | -124 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -72 | -110 | -177 | -96 | -75 |
Depreciation & Amortization (Cash Flow) | 12 | 3 | 3 | 1 | 1 |
Income After Depreciation & Amortization | -83 | -113 | -180 | -97 | -76 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 143.24 | 141.92 | 129.37 | 118.47 | 93.02 |
Diluted EPS Before Non-Recurring Items | -0.54 | -0.76 | -1.40 | -0.87 | -0.89 |
Diluted Net EPS (GAAP) | -0.54 | -0.76 | -1.40 | -0.87 | -1.33 |
Fiscal Year end for Aurinia Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 45.10 | 54.52 | 41.49 | 34.41 |
Cost Of Goods | NA | 5.40 | 6.77 | 1.56 | 0.42 |
Gross Profit | NA | 39.70 | 47.75 | 39.93 | 33.99 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 60.30 | 61.37 | 59.73 | 63.28 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -20.60 | -13.62 | -19.80 | -29.29 |
Non-Operating Income | NA | -4.51 | 1.87 | 7.73 | 3.52 |
Interest Expense | NA | 1.31 | 1.40 | 0.07 | 0.00 |
Pretax Income | NA | -26.42 | -13.15 | -12.13 | -25.77 |
Income Taxes | NA | 0.46 | 0.30 | -0.64 | 0.44 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -26.88 | -13.45 | -11.49 | -26.21 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -26.88 | -13.45 | -11.49 | -26.21 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 142.93 | 142.85 | 142.78 | 142.64 |
Diluted EPS Before Non-Recurring Items | NA | -0.19 | -0.09 | -0.08 | -0.18 |
Diluted Net EPS (GAAP) | NA | -0.19 | -0.09 | -0.08 | -0.18 |